



**KAREN L. SMITH, MD, MPH**  
*Director & State Health Officer*

State of California—Health and Human Services Agency  
**California Department of Public Health**



**GAVIN NEWSOM**  
*Governor*

Office of AIDS (OA)  
AIDS Drug Assistance Program (ADAP)

Management Memorandum  
Memorandum Number: 2019-11

DATE: May 7, 2019

TO: ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF IBALIZUMAB-UIYK (TROGARZO™) TO THE ADAP FORMULARY

**Effective May 3, 2019**, ADAP added Ibalizumab-uiyk (Trogarzo™) to the ADAP formulary.

Ibalizumab-uiyk (Trogarzo™) is a first-in-class CD4-directed post-attachment HIV-1 inhibitor that received federal Food and Drug Administration (FDA) approval on March 6, 2018. The adoption of Trogarzo™ introduces a new class of antiretroviral (ARV) treatment indicated for adult patients who have tried multiple treatments but whose HIV infections has not been successfully treated, including those with multidrug-resistant HIV.

Trogarzo™ is used in combination with other antiretroviral medications and must be administered intravenously once every 14 days by a trained medical professional. Trogarzo™ is not expected to be utilized heavily. Trogarzo is only indicated for individuals with multi-drug resistant HIV and therefore will only be available through the prior authorization process.

ADAP's Medical Advisory Committee (MAC) recommends the addition of Trogarzo™. ADAP worked with Magellan Rx to establish processes to deliver and administer Trogarzo™ with as little disruption to the client as possible. For questions on how to access Trogarzo, please call Magellan Rx at: 1(800) 424-5906.

May 7, 2019

Page 2

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The [ADAP drug formulary](https://cdph.magellanrx.com/member/documents) has been updated to reflect the addition of Trogarzo™. Access the updated formulary at the following URL: <https://cdph.magellanrx.com/member/documents>.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you,

A handwritten signature in blue ink, appearing to read 'Sandra Robinson', with a stylized flourish at the end.

Sandra Robinson, MBA  
ADAP Branch Chief  
California Department of Public Health